I don't know any easy solutions to the low replication rate of many areas right now. It seems to be fundamentally a systematic problem of incentives. Even the easiest and most basic remedies like clinical trial registries are not being enforced, so it's hopeless to expect reforms like making all studies well-powered. I do think that increasing alpha is unlikely to fix the problems and is likely to backfire by making things worse and rewarding cheaters & punishing honest researchers: the smaller the p-value required, the more you reward people who can run hundreds of analyses to get a p-value under the threshold and the more you punish honest researchers who did one analysis and stuck with it.